Download PDF
Semin Respir Crit Care Med 2013; 34(06): 727-737
DOI: 10.1055/s-0033-1358549
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Lung Cancer Screening

Douglas Arenberg
1   Division of Pulmonary & Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
20 November 2013 (online)

    Permissions and Reprints

Abstract

The National Lung Screening Trial demonstrated that lung cancer screening with three annual low-dose computed tomographic scans has the potential to reduce lung cancer–specific mortality by 20% in an older population of heavy smokers. This was a great achievement by the National Lung Screening Trial (NLST) investigators, but this should be viewed as an important first step in an unfinished process. Many major questions remain about how to best realize this mortality reduction in a practical real-world context. Screening for lung cancer will be most effective if it is accompanied by continued research into risk modeling, patient communication strategies, and biomarkers. For clinicians establishing a program of lung cancer screening, we encourage this to be done in a responsible fashion, adhering to practices specified in the design of the NLST, and with careful attention given to proper management of screen-detected abnormalities and maintenance of screening registries.

Keywords

screening - CT scan - lung nodule - lung cancer - mortality
 

  • References

  • 1 Aberle DR, Adams AM, Berg CD , et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (5) 395-409
    CrossrefPubMedGoogle Scholar
  • 2 Aberle DR, Berg CD, Black WC , et al; National Lung Screening Trial Research Team. The National Lung Screening Trial: overview and study design. Radiology 2011; 258 (1) 243-253
    CrossrefPubMedGoogle Scholar
  • 3 Feinstein MB, Bach PB. Epidemiology of lung cancer. Chest Surg Clin N Am 2000; 10 (4) 653-661
    PubMedGoogle Scholar
  • 4 Bach PB, Kattan MW, Thornquist MD , et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95 (6) 470-478
    CrossrefPubMed
  • 5 Cassidy A, Myles JP, van Tongeren M , et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008; 98 (2) 270-276
    CrossrefPubMedGoogle Scholar
  • 6 Spitz MR, Hong WK, Amos CI , et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007; 99 (9) 715-726
    CrossrefPubMedGoogle Scholar
  • 7 Tammemägi MC, Katki HA, Hocking WG , et al. Selection criteria for lung-cancer screening. N Engl J Med 2013; 368 (8) 728-736
    CrossrefPubMedGoogle Scholar
  • 8 Kovalchik SA, Tammemagi M, Berg CD , et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013; 369 (3) 245-254
    CrossrefPubMedGoogle Scholar
  • 9 D'Amelio Jr AM, Cassidy A, Asomaning K , et al. Comparison of discriminatory power and accuracy of three lung cancer risk models. Br J Cancer 2010; 103 (3) 423-429
    CrossrefPubMedGoogle Scholar
  • 10 Gliklich RE, Dreyer NA. Registries for evaluating patient outcomes: a user's guide. Rockville, MD: US Dept. of Health and Human Services. Public Health Service, Agency for Healthcare Research and Quality; 2007
    Google Scholar
  • 11 Le Marchand L, Hankin JH, Bach F , et al. An ecological study of diet and lung cancer in the South Pacific. Int J Cancer 1995; 63 (1) 18-23
    CrossrefPubMedGoogle Scholar
  • 12 Gorlova OY, Weng SF, Hernandez L, Spitz MR, Forman MR. Dietary patterns affect lung cancer risk in never smokers. Nutr Cancer 2011; 63 (6) 842-849
    CrossrefPubMedGoogle Scholar
  • 13 Pande M, Spitz MR, Wu X, Gorlov IP, Chen WV, Amos CI. Novel genetic variants in the chromosome 5p15.33 region associate with lung cancer risk. Carcinogenesis 2011; 32 (10) 1493-1499
    CrossrefPubMedGoogle Scholar
  • 14 Gao WM, Kuick R, Orchekowski RP , et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005; 5: 110
    CrossrefPubMedGoogle Scholar
  • 15 Field JK, Brambilla C, Caporaso N , et al. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol 2002; 21 (2) 369-373
    PubMedGoogle Scholar
  • 16 Gorlova OY, Amos C, Henschke C , et al. Genetic susceptibility for lung cancer: interactions with gender and smoking history and impact on early detection policies. Hum Hered 2003; 56 (1-3) 139-145
    CrossrefPubMedGoogle Scholar
  • 17 Spitz MR, Etzel CJ, Dong Q , et al. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila) 2008; 1 (4) 250-254
    CrossrefPubMedGoogle Scholar
  • 18 Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998; 317 (7154) 307-312
    CrossrefPubMedGoogle Scholar
  • 19 Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Intern Med 2012; 157 (8) 571-573
    CrossrefPubMedGoogle Scholar
  • 20 Swensen SJ, Jett JR, Hartman TE , et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005; 235 (1) 259-265
    CrossrefPubMedGoogle Scholar
  • 21 Henschke CI, Yip R, Yankelevitz DF, Smith JP ; International Early Lung Cancer Action Program Investigators*. Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. Ann Intern Med 2013; 158 (4) 246-252
    CrossrefPubMedGoogle Scholar
  • 22 Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. Chest 2013; 143 (3) 672-677
    CrossrefPubMedGoogle Scholar
  • 23 Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS ; International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355 (17) 1763-1771
    CrossrefPubMedGoogle Scholar
  • 24 Hassan C, Giorgi Rossi P, Camilloni L , et al; HTA Group. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 2012; 36 (10) 929-940
    CrossrefPubMedGoogle Scholar
  • 25 Jacobs PCA, Mali WPTM, Grobbee DE, van der Graaf Y. Prevalence of incidental findings in computed tomographic screening of the chest: a systematic review. J Comput Assist Tomogr 2008; 32 (2) 214-221
    CrossrefPubMedGoogle Scholar
  • 26 Yu H, Zhao H, Wang LE , et al. An analysis of single nucleotide polymorphisms of 125 DNA repair genes in the Texas genome-wide association study of lung cancer with a replication for the XRCC4 SNPs. DNA Repair (Amst) 2011; 10 (4) 398-407
    CrossrefPubMedGoogle Scholar
  • 27 Maisonneuve P, Bagnardi V, Bellomi M , et al. Lung cancer risk prediction to select smokers for screening CT—a model based on the Italian COSMOS trial. Cancer Prev Res (Phila) 2011; 4 (11) 1778-1789
    CrossrefPubMedGoogle Scholar
  • 28 Albert JM. Radiation risk from CT: implications for cancer screening. AJR Am J Roentgenol 2013; 201 (1) W81-7
    PubMedGoogle Scholar
  • 29 Brenner DJ. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology 2004; 231 (2) 440-445
    CrossrefPubMedGoogle Scholar
  • 30 McCollough CH, Chen GH, Kalender W , et al. Achieving routine submillisievert CT scanning: report from the summit on management of radiation dose in CT. Radiology 2012; 264 (2) 567-580
    CrossrefPubMedGoogle Scholar
  • 31 Raff GL. Radiation dose from coronary CT angiography: five years of progress. J Cardiovasc Comput Tomogr 2010; 4 (6) 365-374
    CrossrefPubMedGoogle Scholar
  • 32 Foy M, Spitz MR, Kimmel M, Gorlova OY. A smoking-based carcinogenesis model for lung cancer risk prediction. Int J Cancer 2012; 129 (8) 1907-1913
    PubMedGoogle Scholar
  • 33 Ebbert JO, Yang P, Vachon CM , et al. Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 2003; 21 (5) 921-926
    CrossrefPubMedGoogle Scholar
  • 34 Field M, Mogg K, Bradley BP. Automaticity of smoking behaviour: the relationship between dual-task performance, daily cigarette intake and subjective nicotine effects. J Psychopharmacol 2006; 20 (6) 799-805
    CrossrefPubMedGoogle Scholar
  • 35 Jorenby DE, Leischow SJ, Nides MA , et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340 (9) 685-691
    CrossrefPubMedGoogle Scholar
  • 36 Jorenby DE, Hays JT, Rigotti NA , et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1) 56-63
    CrossrefPubMedGoogle Scholar
  • 37 Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR ; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1) 64-71
    CrossrefPubMedGoogle Scholar
  • 38 Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 2002; 121 (3) 932-941
    CrossrefPubMedGoogle Scholar
  • 39 Lafata JE, Simpkins J, Lamerato L, Poisson L, Divine G, Johnson CC. The economic impact of false-positive cancer screens. Cancer Epidemiol Biomarkers Prev 2004; 13 (12) 2126-2132
    PubMedGoogle Scholar
  • 40 Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001; 345 (3) 181-188
    CrossrefPubMedGoogle Scholar
  • 41 MacMahon H, Austin JHM, Gamsu G , et al; Fleischner Society. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005; 237 (2) 395-400
    CrossrefPubMedGoogle Scholar
  • 42 Naidich DP, Bankier AA, MacMahon H , et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013; 266 (1) 304-317
    CrossrefPubMedGoogle Scholar
  • 43 Lin M, Stewart DJ, Spitz MR , et al. Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 2011; 32 (7) 1050-1056
    CrossrefPubMedGoogle Scholar
  • 44 Gould MK, Donington J, Lynch WR , et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e93S-e120S
    CrossrefPubMedGoogle Scholar
  • 45 Gould MK, Ananth L, Barnett PG ; Veterans Affairs SNAP Cooperative Study Group. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest 2007; 131 (2) 383-388
    CrossrefPubMedGoogle Scholar
  • 46 Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 1997; 157 (8) 849-855
    CrossrefPubMedGoogle Scholar
  • 47 Ceniza SV, Balili ER, Canete MTA, Abrigonda JJM, Rafanan AL. A clinical prediction model for estimating the probability of malignancy of a solitary pulmonary nodule in the Philippine setting [abstract]. Chest 2010; 138 (4, Meeting Abstracts) 725A
    CrossrefPubMedGoogle Scholar
  • 48 Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e166S-e190S
    CrossrefPubMedGoogle Scholar
  • 49 Alberts WM ; American College of Chest Physicians. Introduction: diagnosis and management of lung cancer: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007; 132 (3, Suppl): 20S-22S
    CrossrefPubMedGoogle Scholar
  • 50 Sigurdson AJ, Jones IM, Wei Q , et al. Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Carcinogenesis 2011; 32 (1) 69-73
    CrossrefPubMedGoogle Scholar
  • 51 Sox HC. Better evidence about screening for lung cancer. N Engl J Med 2011; 365 (5) 455-457
    CrossrefPubMedGoogle Scholar
  • 52 Nease Jr DE, Ruffin IV MT, Klinkman MS, Jimbo M, Braun TM, Underwood JM. Impact of a generalizable reminder system on colorectal cancer screening in diverse primary care practices: a report from the prompting and reminding at encounters for prevention project. Med Care 2008; 46 (9) (Suppl. 01) S68-S73
    CrossrefPubMedGoogle Scholar
  • 53 Ruffin IV MT, Creswell JW, Jimbo M, Fetters MD. Factors influencing choices for colorectal cancer screening among previously unscreened African and Caucasian Americans: findings from a triangulation mixed methods investigation. J Community Health 2009; 34 (2) 79-89
    CrossrefPubMedGoogle Scholar
  • 54 Ruffin IV MT, Fetters MD, Jimbo M. Preference-based electronic decision aid to promote colorectal cancer screening: results of a randomized controlled trial. Prev Med 2007; 45 (4) 267-273
    CrossrefPubMedGoogle Scholar
  • 55 Silvestri GA, Nietert PJ, Zoller J, Carter C, Bradford D. Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts. Thorax 2007; 62 (2) 126-130
    CrossrefPubMedGoogle Scholar
  • 56 Tammemägi MC, Katki HA, Hocking WG , et al. Selection criteria for lung-cancer screening. N Engl J Med 2013; 368 (8) 728-736
    CrossrefPubMedGoogle Scholar
  • 57 Chou R, Croswell JM, Dana T , et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155 (11) 762-771
    CrossrefPubMedGoogle Scholar
  • 58 Andriole GL, Crawford ED, Grubb III RL , et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360 (13) 1310-1319
    CrossrefPubMedGoogle Scholar
  • 59 Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998; 317 (7154) 307-312
    CrossrefPubMedGoogle Scholar
  • 60 Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L ; U.S. Preventive Services Task Force. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151 (10) 727-737 , W237-42
    CrossrefPubMedGoogle Scholar
  • 61 Greif JM. Mammographic screening for breast cancer: an invited review of the benefits and costs. Breast 2010; 19 (4) 268-272
    CrossrefPubMedGoogle Scholar
  • 62 Sharaf RN, Ladabaum U. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Am J Gastroenterol 2013; 108 (1) 120-132
    CrossrefPubMedGoogle Scholar
  • 63 Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2012; 9 (12) e1001352
    CrossrefPubMedGoogle Scholar
  • 64 Oken MM, Hocking WG, Kvale PA , et al; PLCO Project Team. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011; 306 (17) 1865-1873
    CrossrefPubMedGoogle Scholar